Aptorum Group’s Subsidiary - Claves Life Sciences Limited Establishes Novel Therapeutic Platform for Treatment of Various D...

日付 : 2019/05/06 @ 21 : 00
情報提供 : ビジネスワイヤ(英語)
銘柄名 : Aptorum Group Ltd (APM)
株価 : 3.35  +0.2044 (6.50%) @ 09 : 00
Aptorum 銘柄情報 チャート
After Hours
Last Trade
Last $ 3.35 ◊ 0.00 (0.00%)

Aptorum Group’s Subsidiary - Claves Life Sciences Limited Establishes Novel Therapeutic Platform for Treatment of Various D...

Aptorum (NASDAQ:APM)
過去 株価チャート

から 6 2018 まで 6 2020


Claves Life Sciences Limited, a wholly owned subsidiary of Aptorum Group Limited ("Aptorum") (Nasdaq: APM), is excited to announce the establishment of a novel therapeutic platform for the treatment of various diseases via modulation of the chemical signaling relating to gut microbiota. The role of gut microbiota in the pathogenesis of various diseases has been under the spotlight recently. It has been demonstrated that gut microbiota is related to major diseases such as metabolic and cardiovascular diseases1,2, cancer3, neurodegenerative diseases4, etc.

“With the continuous discovery of the role played by gut microbiota in various diseases, we believe that novel therapeutic targets will be subsequently identified and defined. As a result, we believe that the therapeutic potential of our platform is unlimited at present and for the future", expressed by Mr. Ian Huen, the CEO of Aptorum. Through our collaboration with local universities, our initial focus is currently on metabolic and cardiovascular diseases. We are targeting to move our drug candidates to Ph 1 clinical trial by 2020 - 2021.

1Nature Communications 8: 845 (2017)

2BMB Rep. 2016 Oct 31; 49(10): 536–541



About Aptorum Group Limited

Aptorum Group Limited (Nasdaq: APM) is a pharmaceutical company dedicated to developing and commercializing a broad range of therapeutic and diagnostic technologies to tackle unmet medical needs. Aptorum Group is pursuing therapeutic and diagnostic projects in neurology, infectious diseases, gastroenterology, oncology and other disease areas as well as non-therapeutic areas such as surgical robotics and the operations of its medical clinic in Hong Kong, Talem Medical, with the initial focus on treatment of chronic diseases resulting from modern sedentary lifestyles and aging population.

For more information about Aptorum Group, please visit www.aptorumgroup.com.

About Claves Life Sciences Limited

Claves Life Sciences Limited is a wholly-owned therapeutics subsidiary of Aptorum Group Limited. Claves focuses on the clinical development in therapeutic candidates related to the field of gastroenterology. The potential candidates under review and potentially developed focus on the modulation of gut microbiota derived metabolites, for preventing or treating diseases. Claves is also exploring a gut microbiota modulation platform that can generate novel custom candidates capable of fine-tuning levels of gut metabolites, potentially treating a wide range of medical conditions.

Disclaimer and Forward-Looking Statements

This press release includes statements concerning Aptorum Group Limited and its future expectations, plans and prospects that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” or “continue,” or the negative of these terms or other similar expressions. Aptorum Group has based these forward-looking statements largely on its current expectations and projections about future events and trends that it believes may affect its business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions including, without limitation, risks related to its announced management and organizational changes, the continued service and availability of key personnel, its ability to expand its product assortments by offering additional products for additional consumer segments, the company’s anticipated growth strategies, anticipated trends and challenges in its business, and its expectations regarding, and the stability of, its supply chain, and the risks more fully described in Aptorum Group’s Form 20-F and other filings that Aptorum Group may make with the SEC in the future. Aptorum Group assumes no obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

Investors:Tel: +852 2117 6611Email: investor.relations@aptorumgroup.comMedia:Tel: + 852 2117 6611Email: info@aptorumgroup.com



LSEとPLUSのデータはリアルタイムで表示されています。 東証、福証、札証、NYSE及びAMEXのデータは実際の取引から最低20分遅れで表示されています。
P: V:jp D:20200606 17:54:40